Get the Stockscreener App
11.29
0.13%
0.015
Compass Pathways Plc Adr stock is traded at $11.29, with a volume of 951.91K.
It is up +0.13% in the last 24 hours and down -18.28% over the past month.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
See More
Previous Close:
$11.27
Open:
$11.25
24h Volume:
951.91K
Relative Volume:
0.36
Market Cap:
$1.56B
Revenue:
Net Income/Loss:
$-191.97M
P/E Ratio:
-3.574
EPS:
-3.1575
Net Cash Flow:
$-159.63M
1W Performance:
-1.61%
1M Performance:
-18.28%
6M Performance:
+89.35%
1Y Performance:
+65.23%
1-Day Range:
$11.15
$11.44
1-Week Range:
$10.97
$12.07
52-Week Range:
$4.88
$15.87
Compass Pathways Plc Adr Stock (CMPS) Company Profile
Name
Compass Pathways Plc Adr
Sector
Industry
Phone
1-716-676-6461
Address
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE
Compare CMPS vs HCA, THC, EHC, DVA, FMS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPS
Compass Pathways Plc Adr
|
11.29 | 1.56B | 0 | -191.97M | -159.63M | -3.1575 |
HCA
Hca Healthcare Inc
|
468.32 | 101.39B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
274.38 | 22.09B | 21.46B | 2.65B | 3.35B | 19.23 |
EHC
Encompass Health Corp
|
128.12 | 12.64B | 6.07B | 793.80M | 464.40M | 5.9914 |
DVA
Davita Inc
|
186.65 | 11.91B | 13.84B | 1.10B | 1.49B | 10.42 |
FMS
Fresenius Medical Care Ag Adr
|
22.12 | 11.77B | 22.44B | 1.35B | 2.03B | 1.9002 |
Compass Pathways Plc Adr Stock (CMPS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-26 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-26 | Upgrade | Evercore ISI | In-line → Outperform |
| May-22-26 | Initiated | Wolfe Research | Outperform |
| May-04-26 | Initiated | Jefferies | Buy |
| Apr-24-26 | Initiated | B. Riley Securities | Buy |
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-23-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-27-25 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-01-24 | Initiated | Morgan Stanley | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-22 | Resumed | Berenberg | Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Oct-29-21 | Initiated | Oppenheimer | Outperform |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
| May-11-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-01-21 | Initiated | ROTH Capital | Buy |
| Oct-14-20 | Initiated | H.C. Wainwright | Buy |
| Oct-13-20 | Initiated | Berenberg | Buy |
| Oct-13-20 | Initiated | Canaccord Genuity | Buy |
| Oct-13-20 | Initiated | Cowen | Outperform |
| Oct-13-20 | Initiated | Evercore ISI | Outperform |
View All
Compass Pathways Plc Adr Stock (CMPS) Latest News
CMPS: COMP360 shows durable efficacy in TRD, with launch and broad site readiness expected in the coming year - TradingView
CMPS: COMP360 targets TRD launch in H1 2027, leveraging strong data, payer support, and clinic readiness - tradingview.com
CMPS: Psychedelic therapy for TRD nears FDA approval, promising rapid, durable relief and broad adoption - tradingview.com
CMPS: COMP360's rapid, durable TRD results and robust launch prep signal a paradigm shift in psychiatry - tradingview.com
Fluence to develop psilocybin therapy training for Compass - investing.com
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training - Finviz
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51 - FXEmpire
Compass Pathways stock hits 52-week high at 15.4 USD - investing.com
Compass Pathways stock shows durable results in depression trial - investing.com
Compass Pathfinder Limited: Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year - FinanzNachrichten.de
AQST Stock Price, Quote & News - Syfe
CytomX Therapeutics, Inc. (CTMX) Stock Price & News - Syfe
COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question - sahmcapital.com
Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS) - MarketBeat
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions - Sahm
COMPASS (CMPS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Latest Reading; Session Move: Shares Close 0.79% HigherEarnings Acceleration Picks - dars.gov.et
COMPASS (CMPS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Latest Reading - www.dars.gov.et
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionEarnings Call Transcript - careplusvn.com
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionAdjusted Earnings Analysis - dars.gov.et
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionMargin Compression Risk - dars.gov.et
COMPASS (CMPS) Technical Check: Climbs 1.31% to $13.90 for the Current Session; Level Position: the Near-Term Reference Band Stretches From $13.21 to $14.60 in the Current UpdateChart Pattern Alerts - careplusvn.com
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances - Yahoo Finance
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CMPS: COMP360 targets a 2027 launch, offering rapid, durable relief for TRD and advancing a PTSD program - TradingView
HC Wainwright Cuts Earnings Estimates for Compass Pathways - MarketBeat
COMPASS Pathways (CMPS) insider files Form 144 for 26,000 ADS sale - stocktitan.net
COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run - Sahm
COMPASS Pathways plc (5Y6.F) stock price, news, quote and history - Yahoo Finance Singapore
Renaissance Technologies LLC Reduces Stock Position in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Compass Pathways partners with VA on psilocybin trial for veterans - Investing.com
Compass Pathfinder Limited: Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin - FinanzNachrichten.de
Compass Pathways (NASDAQ:CMPS) Trading 9.8% HigherWhat's Next? - MarketBeat
Earnings call transcript: COMPASS Pathways advances q2 2026 launch plans as stock slips - Investing.com
COMPASS Pathways Reports Q2 2026 Financials and Updates on COMP360 Clinical Programs - Kalkine Media
Why is Compass Pathways stock rallying today? By Investing.com - Investing.com South Africa
Compass Pathways Q2 Earnings Call Highlights - Yahoo Finance
CMPS: Q2 2026 net loss widened to $253.8M; Phase 3 TRD milestones achieved; cash runway into 2028 - TradingView
Seven Fleet Capital Management LP Buys 118,021 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78Volume Breadth - careplusvn.com
200,000 Shares in Compass Pathways PLC Sponsored ADR $CMPS Acquired by Vivo Capital LLC - MarketBeat
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78High Reward Trades - www.dars.gov.et
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78Ratio Spread Trade - dars.gov.et
Compass Pathways earnings on deck ahead of pivotal FDA filing - Investing.com
COMPASS Pathways (CMPS) Slips 3.73% as Stock Nears Key Support at $10.31Continuation Pattern Picks - careplusvn.com
COMPASS Pathways (CMPS) Slips 3.73% as Stock Nears Key Support at $10.31Double EMA - dars.gov.et
Eversept Partners LP Makes New $3.75 Million Investment in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Orbimed Advisors LLC Buys New Shares in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Compass Pathways Plc Adr Stock (CMPS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compass Pathways Plc Adr Stock (CMPS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jenkins Annalisa | Former Director |
Aug 07 '26 |
Proposed Sale |
13.72 |
83,771 |
1,149,153 |
0 |
3.13%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):